A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study.

Barrett, Tristan; Pacey, Simon; Leonard, Kelly; Wulff, Jerome; Funingana, Ionut-Gabriel; Gnanapragasam, Vincent

Barrett, Tristan; Pacey, Simon; Leonard, Kelly; Wulff, Jerome; Funingana, Ionut-Gabriel; Gnanapragasam, Vincent.

Affiliation

Barrett T; Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, UK.
Pacey S; Department of Radiology, University of Cambridge, Cambridge, UK.
Leonard K; Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, UK.
Wulff J; Department of Oncology, University of Cambridge, Cambridge, UK.
Funingana IG; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.
Gnanapragasam V; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK.

Eur Urol Open Sci ; 38: 17-24, 2022 Apr.

Article de En | MEDLINE | ID: mdl-35495285

Mots clés

Active surveillance; Androgen deprivation therapy; Androgen receptor; Apalutamide; Gland volume; MRI; Progression; Prostate cancer; Short term androgen targeted therapy; Tumour to gland volume ratio; Tumour volume

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Prognostic_studies / Screening_studies Aspects: Patient_preference Langue: En Journal: Eur Urol Open Sci Année: 2022 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Pays-Bas

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google